Funding · Series B · 14 August 2026
Mironid raises £34m
Glasgow-based Mironid has raised £34m in a Series B round. The company develops drugs for polycystic kidney disease. Investors include Scottish National Investment Bank, Roche Venture Fund, Epidarex Capital and others. The money will go on clinical development, including first-in-human studies.
80thRound size percentile, 5 series b rounds
Press report
CompanyMironid
StageSeries B
SectorHealthTech
Based inScotland
InvestorsScottish National Investment Bank, Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, University of Strathclyde
SourcePress · confidence highView source ↗
Your note on Mironid
Sign in to keep private notes on this company.
Is this your company?
Hide the valuation estimate straight away, add your investors, or tell us something's wrong. We check every change.